Skip to main content
[Preprint]. 2023 Jun 4:2023.05.31.23290587. [Version 1] doi: 10.1101/2023.05.31.23290587

Table 1.

Patient characteristics (n = 16)

Clinical characteristics ARVC GE patients (n = 8) ARVC PKP2 patients (n = 8) p-value

Male 2 (25) 2 (25) -
Age at CMR, years 31.0 [22–45] 35.3 [18–55] 0.55
Age at first clinical VT, years 34.0 [22–45] 31.0 [17–55] 0.94
ICD implantation 7 (88) 7 (88) -
Beta blocker 8 (100) 5 (63) 0.056
Sodium channel blocker 2 (25) 3 (38) 0.59
Syncope 2 (25) 2 (25) -

Cardiac function

RV hypokinesis 4 (50) 6 (75) 0.15
RVEF (%) 37.6 ± 5.5 36.1 ± 9.7 0.76
RVCO (L/min) 4.7 ± 1.2 4.9 ± 0.9 0.72
RVEDVI (ml/m2) 131.8 ± 31.2 144.5 ± 63.3 0.66
LVEF (%) 57.2 ± 6.5 55.7 ± 10.0 0.74
LVEDVI (ml/m2) 89.3 ± 9.2 89.7 ± 23.0 0.97
LVCO (L/min) 5.1 ± 0.8 5.0 ± 0.9 0.86

Values are given as n%, mean [range], or mean ± standard deviation (SD). p values were calculated using Student’s t-test with p ≤ 0.05 as statistically significant. CMR = cardiac magnetic resonance; VT = ventricular tachycardia; ICD = implantable cardiac defibrillator; RV = right ventricle; LV = left ventricle; RVEF = right ventricular ejection fraction; RVCO = right ventricular cardiac output; RVEDVI = right ventricular end-diastolic volume index; LVEF = left ventricular ejection fraction; LVCO = left ventricular cardiac output; LVEDVI = left ventricular end-diastolic volume index. The cardiac function parameters were obtained from CMR reports.